56 results on '"Galetta, D."'
Search Results
2. A cross-sectional study evaluating the exercise discussion with oncologist during cancer consultation: the CONNECT study
3. Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1
4. LBA2 First-line (1L) durvalumab (D) + platinum-etoposide (EP) for patients (pts) with extensive-stage SCLC (ES-SCLC): Primary results from the phase IIIb LUMINANCE study
5. 1912P AI-based early prediction of radiation pneumonitis in stage III NSCLC patients
6. 1689TiP The social stigma of smokers and patients with lung cancer: Detection of phoenomenon and testing of EMDR (eye movement desensitization and reprocessing) intervention
7. 1283P Advanced ALK-positive non-small cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database
8. Maintenance or non-maintenance therapy in the treatment of advanced non-small cell lung cancer: that is the question
9. 1510TiP Efficacy study of osimertinib in treatment-naïve patients with EGFR mutant non-small cell lung cancer (NSCLC) according to TP53 mutational status (TEMPLE-2/NCT05785208)
10. 2001P Consolidative thoracic radiotherapy of extensive-stage small cell lung cancer in the era of chemoimmunotherapy: A retrospective analysis concerning patients from southern Italy
11. 2128P exerCise discussion with Oncologist duriNg caNcEr ConsultaTion: The CONNECT study
12. RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients
13. Neoadjuvant concurrent radiochemotherapy in locally advanced (IIIA–IIIB) non-small-cell lung cancer: long-term results according to downstaging
14. 1019P Pattern of clinical activity of anticancer vaccine OSE2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (IO) in phase III Atalante-1 randomized trial
15. 125P Radiomic signature from baseline CT Scan to predict initial response to treatment in advanced/unresectable pleural mesothelioma: Preliminary data
16. LBA47 Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (IO): Final results of phase III Atalante-1 randomised trial
17. 1260MO Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): Step 1 results of phase III ATALANTE-1 randomised trial
18. 55P - Incidence and clinical implications of late immune-related adverse events in long responders to PD-1/PD-L1 checkpoint inhibitors: A multicenter study
19. 1746P - Prognostic role of RLF/MYCL1 and circPVT1 in SCLC
20. 1588TiP - The elderly patient individualized chemotherapy (EPIC) trial, a study for an aged population of non-small cell lung cancer
21. 1568P - Post progression survival for patients treated with docetaxel/nintedanib in the SENECA trial
22. 1518P - Pembrolizumab frontline monotherapy in patients with NSCLC and high PD-L1 expression: Real-world data from a European Cohort with focus on subgroups of interest
23. 1489PD - Secondary ROS1 mutations and lorlatinib sensitivity in crizotinib-refractory ROS1 positive NSCLC: Results of the prospective PFROST trial
24. 87P - Time-series of peripheral blood biomarkers as biomarkers for immunotherapy in advanced non-small cell lung cancer (aNSCLC) patients
25. 156P - Peripheral blood biomarkers as prognostic factors for immunotherapy in advanced non-small cell lung cancer (aNSCLC) patients
26. P2 - Post-survey data about “I do not smoke it”, smoking prevention campaign addressed to schools
27. E1* - Crizotinib in ROS1 rearranged or MET deregulated non-small-cell lung cancer (NSCLC): final results of the METROS trial
28. E11 - The close link between anxiety and cluster symptoms in lung cancer patients during first-line chemotherapy: further data from a dedicated WALCE (Women Against Lung Cancer in Europe) survey
29. E8 - Efficacy of ceritinib administered to patients with crizotinib-refractory, ALK-positive, advanced NSCLC within the Italian compassionate use program
30. E2 - ASTRIS, a real world treatment study of osimertinib in patients (pts) with EGFR T790M positive non-small cell lung cancer (NSCLC): preliminary analysis of the Italian cohort
31. 1156P - Italian nivolumab expanded access programme: real-world results in non-squamous non-small cell lung cancer patients
32. 1235P - Tumor heterogeneity affects the activity of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR mutant non-small cell lung cancer (NSCLC) patients (pts)
33. 1258P - Intercalated combination of chemotherapy and epidermal growth factor receptor inhibitors for patients with advanced non-small-cell lung cancer: A systematic review and meta-analysis
34. A25 - The role of health professionals in informing patients with pulmonary diseases to stop smoking: final data of an Italian multicentric survey
35. A21 - Chemotherapy-induced nausea and vomiting (CINV) in patients with stage III/IV lung cancer during the first-line treatment: assessment by physician, nurse and patient. Preliminary results from an Italian multicenter survey
36. A11 - Molecular profiling in advanced non-small-cell lung cancer: preliminary data of the Italian observational prospective study
37. A09 - Intercalated chemotherapy and epidermal growth factor receptor inhibitors for patients with advanced non-small-cell lung cancer: a systematic review and meta-analysis
38. A03* - Tumor heterogeneity affects the activity of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR mutant non-small cell lung cancer (NSCLC) patients (pts)
39. A01* - Italian cohort of nivolumab Expanded Access Programme (EAP): efficacy and safety data from a real-world population
40. P07 - Maintenance Therapy (MT) for non-squamous advanced NSCLC: a multicenter Italian survey about patients (pts)' perspectives and physicians' awareness
41. N17 - An interdisciplinary early simultaneous palliative approach in metastatic non-small cell lung cancer: preliminary data in outpatient setting
42. H09 - The role of health care professionals in smoking cessation among patients with pulmonary diseases: an Italian multicentric survey
43. H03* - Circulating-free tumor DNA as a surrogate for determination of EGFR status: the Italian experience within the ASSESS study
44. 1278P - Be-Positive: Beyond Progression After Tyrosine Kinase Inhibitor in Egfr-Positive Non-Small Cell Lung Cancer (Nsclc) Patients. Preliminary Results from a Multicenter Italian Observational Study
45. 1288P - Efficacy of the Irreversible EGFR-HER2 Dual Inhibitor Afatinib in Pretreated Lung Adenocarcinoma
46. 40 ThinPrepR CYTOLOGICAL SPECIMENS ARE OFTEN MORE SUITABLE THAN HISTOLOGICAL SPECIMENS TO DETECT EGFR AND K-RAS MUTATIONS IN NSCLC AND COLORECTAL CARCINOMA
47. 5 PANITUMUMAB PLUS CHEMOTHERAPY AS SALVAGE TREATMENT IN PRETREATED ADVANCED COLORECTAL CANCER PATIENTS: A SINGLE INSTITUTION'S EXPERIENCE
48. 9085 A platinum based second line rechallenge chemotherapy improves survival in small cell lung cancer patients
49. First-line cisplatin (P) with docetaxel (TXT) or vinorelbine (VNR) in patients with advanced non-small-cell lung cancer: A phase II randomized trial of Gruppo Oncologico Italia Meridionale
50. Activity and tolerability of Cisplatin (CDDP) and Fotemustine (FTM) combination in the treatment of patients with non-small cell lung cancer (NSCLC) with brain metastases (BM): A multicentric phase II study of the Gruppo Oncologico dell’Italia Meridionale (GOIM)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.